Vaccines for preventing dengue infection

Abstract

Reason for withdrawal from publication Authors have made no progress with this protocol since 2008. In July 2016, the World Health Organization published a position paper regarding the introduction and use of the registered Dengue vaccine, CYD-TDV (http://www.who.int/wer/2016/wer9130.pdf?ua=1). The length of time already spent on this review with little progress, and this position paper mean that a full review at this stage (December 2016) would probably not further assist policy-makers. The decision has therefore been taken to withdraw the protocol. Notes for 'Types of outcome measures' Definition of dengue infections Asymptomatic or mild dengue: no obvious clinical signs but laboratory confirmation of acute or recent infection. Dengue fever (DF): clinical symptoms such as high fever, headache, muscle pain, eye pain, bone pain, and rash. Dengue haemorrhagic fever (DHF): clinical symptoms as for DF, including haemorrhagic manifestations, plasma leakage, and thrombocytopenia. DHF with dengue shock syndrome (DSS): clinical symptoms as for DHF including circulatory failure, haemoconcentration, and hypovolemic shock. Definition of severe dengue: DHF with or without DSS (see above). Methods for laboratory confirmation of dengue virus infection (a) Acute infection. Seroconversion by a 4-fold or larger increase in immunoglobulin, IgG or IgM titre detected by: enzyme linked immuno assay (ELISA); haemaglutination inhibition (HI); or plaque reduction neutralization test (PRNT). Viremia detected by: virus isolation; or reverse transcriptase polymerase reaction (RT-PCR). Recent infection (within previous 3 months). IgM antibodies detected by: ELISA; HI; PRNT; or rapid enzyme linked immuno-sorbent assays (kit formats).